论文信息 - Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) - 字舞流文

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

C. Bloomfield | R. Larson | W. Stock | J. Kolitz | R. Stone | G. Marcucci | Weiqiang Zhao | S. Geyer | W. Blum | G. Uy | M. Wetzler | T. Pardee | Ann-Kathrin Eisfeld | Andrew J Caroll | D. Bucci